Opiant’s opioid antagonist nasal spray technology can be used to treat a range of substance use and eating disorders. A major advantage of administering an opioid antagonist nasally is the rapid onset of action, similar to an injection. For example, a recent brain imaging study demonstrated greater than 90% of mu opioid receptors were rapidly occupied following a 4mg dose of intranasal naloxone. This rapid onset enables a patient to administer the treatment either while in an environment associated with unwanted behavior (e.g., at a restaurant or bar) or anticipating an unwanted behavior (for example, a food binge). This ‘as needed’ dosing reduces the burden of taking a regularly-scheduled dose, giving the patient more control with the potential of improving medication adherence and tolerability. The speed of delivery and onset following intranasal dosing maximizes the potential for disrupting the activation of reward circuitry, reducing the frequency of unwanted behaviors over time.